Palo Santo’s $35M fund investing in the future of psychedelic therapeutics
Palo Santo’s $35M fund investing in the future of psychedelic therapeutics
Business Trip, a podcast about psychedelic entrepreneurship
Welcome back to Business Trip, a podcast about psychedelic entrepreneurship! 🍄
In Episode 16, we chat with Tim Schlidt, a partner at Palo Santo which is a $35M fund investing in psychedelic therapeutics. Palo Santo’s portfolio includes companies like Eleusis, Tactogen, and Journey Clinical.
In this episode, we discuss:
Tim’s background in healthcare finance
Investing in classic psychedelic compounds vs. 2nd generation compounds
Hallmarks of a good first meeting with a prospective investment
Listen to the episode here, on Spotify or Apple Podcasts.
When you’re done listening, tweet at us @businesstripfm to share your thoughts!
About Us
Business Trip tells the story of the emerging industry of psychedelics. Each episode features a new company in the field, ranging from biotech startups developing novel compounds, to clinics and retreats for healing, to software companies building tools to power the ecosystem.
Business Trip is produced by Greg Kubin and Matias Serebrinsky — we’re advocates of the healing powers of psychedelic medicine and see a bright future ahead for the industry.
Thanks for listening,
💖 Know someone who would enjoy Business Trip?